Evidence map›Paper›PMID 35702687›Full record

ArticleClinical ophthalmology (Auckland, N.Z.)2022

Pachymetric Assessment After EpiSmart

Neel S Vaidya, Arvin Daneshmand, Randy J Epstein, Parag A Majmudar, Michael W Belin, Edward C Parsons, Roy S Rubinfeld

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Clinical ophthalmology (Auckland, N.Z.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01097447 (Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01097447 terminatednot on this map

Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas

TypeobservationalSponsorCxlusaRan2009 to 2017Enrolled2,619ConditionsKeratoconus, Ectasia, Degeneration
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Neel S VaidyaChicago Cornea Consultants, Highland Park, IL, USA.
Arvin DaneshmandGeorgetown University Medical School, Washington, DC, USA.
Randy J EpsteinChicago Cornea Consultants, Highland Park, IL, USA.
Parag A MajmudarChicago Cornea Consultants, Highland Park, IL, USA.
Michael W BelinDepartment of Ophthalmology, University of Arizona, Tucson, AZ, USA.
Edward C ParsonsCXL Ophthalmics, LLC, Encinitas, CA, USA.ORCID 0000-0003-2690-0528
Roy S RubinfeldCXL Ophthalmics, LLC, Encinitas, CA, USA.
Rush University Medical Center · USGeorgetown University · USGeorge Washington University Hospital · USUniversity of Arizona · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To assess the change in corneal pachymetry after a novel epithelium-on (EpiSmart Methods: Eyes treated as part of the open-label, non-controlled arm of the study "Collagen Crosslinking with Ultraviolet-A in Asymmetric Corneas" (NCT01097447) were examined at baseline, 3-, 6- and 12-months post-CXL. Thinnest pachymetry readings based on Pentacam (OCULUS GmbH, Wetzlar, Germany) were recorded. Results: A total of 101 eyes met the study inclusion criteria. Thinnest pachymetric readings at baseline averaged 451 ± 50 microns. The mean (± SD) minimum thickness was 450 ± 46 microns at 3 months, 452 ± 47 microns at 6 months, and 451 ± 48 microns at 12 months post-CXL. The changes from baseline (mean ± SE) at 3, 6, and 12 months post-CXL were -1.2 ± 1.5 microns, 0.5 ± 1.6 microns, and 0.4 ± 1.6 microns, respectively. Student's t-tests showed no statistically significant change in pachymetry from baseline for any exam period. Conclusion: This study demonstrated that, after EpiSmart

Indexed as

corneal thinningcross-linkingepithelium-onkeratoconuspachymetrypost-surgical ectasia

Identifiers

PMID35702687
PMCPMC9188777
OpenAlexW4281803088

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.